Literature DB >> 8258333

Selection of internalization-deficient cells by interleukin-2-Pseudomonas exotoxin chimeric protein: the cytoplasmic domain of the interleukin-2 receptor beta chain does not contribute to internalization of interleukin-2.

R K Furse1, T R Malek.   

Abstract

To study the structural basis of ligand-induced receptor-mediated internalization of interleukin-2 (IL-2), a strategy has been developed to generate variant T cells that are deficient in internalization of this cytokine. IL-2 receptor (IL-2R) alpha- and beta-bearing EL4 cells, that express high-affinity IL-2R and internalize IL-2, were treated with low doses of IL-2-Pseudomonas exotoxin chimeric protein (IL-2-PE40). This treatment resulted in isolation of a variant (CX1) that was unable to express high-affinity IL-2R or internalize IL-2. Transfection of CX1 with the IL-2R beta cDNA led to surface expression of IL-2R beta and high-affinity IL-2R as well as the ability to internalize IL-2. This finding indicates that the absence of the beta subunit was the sole defect in CX1 responsible for its failure to internalize IL-2. By transfecting CX1 with mutated beta cDNA, several CX1 transfectants were produced that expressed a beta-subunit that lacked all amino acids of the intracytoplasmic region. These transfectants expressed high-affinity IL-2R and internalized IL-2 at a rate comparable to cells expressing wild-type beta-chain. These results demonstrate that internalization of IL-2 is independent of any signals contained in the intracytoplasmic tail of the beta subunit and raise the possibility that such signals may be entirely contained within the gamma subunit.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258333     DOI: 10.1002/eji.1830231221

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

1.  IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.

Authors:  Akiva Mintz; Denise M Gibo; Becky Slagle-Webb; Neil D Christensen; Waldemar Debinski
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

2.  Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment.

Authors:  Daniel O Villarreal; Michael J Allegrezza; Melissa A Smith; Diana Chin; Leopoldo L Luistro; Linda A Snyder
Journal:  Oncotarget       Date:  2017-11-24

3.  Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.

Authors:  D Salard; T M Kuzel; E Samuelson; S Rosen; O Bakouche
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.542

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.